Uni-Bio Science has developed a strong competitive portfolio of market-leading products in diabetes, ophthalmology and dermatology across China. We are also committed to developing next-generation innovative therapies and have a growing pipeline of drug candidates with €'blockbuster'€ potential that are complementary to our existing portfolio. We are focused on broadening our portfolio through our dual-pronged strategy to research and develop new medicines in-house and through strategic in-licensing. We apply a strict criteria to identifying 'new candidates' all must address a significant medical need in Chinese healthcare and demonstrate a strong market access positioning. Our products are manufactured at our state-of-the-art cGMP certified plants in Beijing and Shenzhen.